Itraconazole Oral Dosing
For fluconazole-refractory oropharyngeal candidiasis, use itraconazole oral solution 200 mg once daily, and for esophageal candidiasis, use 100 mg daily for a minimum of 3 weeks (up to 200 mg daily based on response). 1, 2
Dosing by Indication
Oropharyngeal Candidiasis
Standard treatment:
- 200 mg (20 mL) daily for 1-2 weeks for typical oropharyngeal candidiasis 2
- Vigorously swish 10 mL at a time in mouth for several seconds before swallowing 2
Fluconazole-refractory disease:
- 100 mg (10 mL) twice daily 1, 2
- Clinical response typically seen in 2-4 weeks 2
- This represents a strong recommendation with moderate-quality evidence from IDSA guidelines 1
Esophageal Candidiasis
- 100 mg (10 mL) daily for minimum 3 weeks 2
- Continue for 2 weeks following symptom resolution 2
- May increase to 200 mg (20 mL) daily based on clinical response 2
Aspergillosis
Invasive pulmonary aspergillosis (salvage therapy):
- Tablets: 600 mg/day for 3 days, then 400 mg/day 3
- IV formulation: 200 mg every 12 hours for 2 days, then 200 mg daily 3
Chronic cavitary pulmonary aspergillosis:
- Long-term therapy required; specific dosing follows invasive disease protocols 3
Allergic bronchopulmonary aspergillosis:
- Standard dosing with corticosteroid-sparing effect 3
Critical Formulation Differences
Oral solution vs. capsules are NOT interchangeable 2:
- Oral solution: Take WITHOUT food for optimal absorption 2
- Capsules: Require acidic environment; take WITH food
- Only oral solution is FDA-approved and demonstrated effective for oropharyngeal/esophageal candidiasis 2
Therapeutic Drug Monitoring
Target trough concentrations vary by indication:
For invasive fungal infections:
- Prophylaxis: ≥0.25 mg/L minimum 4
- Treatment: ≥0.5 mg/L minimum 4
- Upper limit: <1.0 mg/L to avoid hepatotoxicity 4
- Standard therapeutic range often cited as 0.5-4.0 mg/L 5
Critical monitoring considerations:
- Capsule formulations frequently produce subtherapeutic levels—22-44% of patients may have undetectable concentrations 6, 5
- Measure trough levels at steady-state (≥7 days after initiation) 6, 5
- If levels ≤0.8 mg/L with clinical deterioration, strongly consider dose escalation 6
Common Pitfalls
Absorption variability with capsules:
- Capsule bioavailability is highly variable and often inadequate 6, 5
- In chronic pulmonary aspergillosis, median capsule concentrations were only 0.30 mg/L despite standard 200 mg twice daily dosing 6
- Solution formulation provides more reliable absorption 2
Relapse rates:
- Patients with oropharyngeal candidiasis commonly relapse shortly after discontinuation 2
- Chronic suppressive therapy (fluconazole 100 mg three times weekly) may be needed for recurrent infections 1
Drug interactions:
- Itraconazole has significant interaction potential that may limit clinical utility 7
- Monitor carefully when co-administering with other medications